Carl June

2 weeks ago | deepnewz.com | Carl June |Bruce Levine |Isabelle Riviere

5 posts • GPT (4.1 mini)Published Jun 12, 2025, 10:17 AMMary-Claire King, an American geneticist renowned for discovering the breast cancer gene, has been awarded the Princess of Asturias Award for Scientific and Technical Research. This recognition highlights her significant contributions to genetics and cancer research. More breaking stories on DeepNewz — updated live.

2 weeks ago | deepnewz.com | Carl June |Bruce Levine |Isabelle Riviere

Daily market recaps with key events, stock movements, and global influences7 posts • GPT (4.1 mini)Published Jun 10, 2025, 07:42 PMBioNTech founders Özlem Türeci and Uğur Şahin have been awarded the 2025 German National Prize in recognition of their contributions to cancer research and the development of one of the world's first effective Covid-19 vaccines.

1 month ago | deepnewz.com | NGS-Guided Treatments With |Carl June |Bruce Levine |Isabelle Riviere

Daily market recaps with key events, stock movements, and global influences5 posts • GPT (4.1 mini)Published May 29, 2025, 07:01 PMResearchers are advancing cancer treatment by developing methods to engineer CAR T cells directly inside the human body, potentially transforming the current process that involves removing and reprogramming T cells externally. This in vivo approach aims to make CAR T cell therapy more accessible and less costly compared to traditional laboratory manufacturing.

Aug 5, 2024 | nature.com | Georg Schett |Fabian Müller |Wei Qing Wang |Franco Locatelli |Carl June

AbstractChimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for patients with relapsed or refractory B cell malignancies. In addition, the administration of genetically modified T cells with the capacity to deplete B cells and/or plasma cells has tremendous therapeutic potential in autoimmune diseases.

Jun 8, 2024 | cell.com | Regina Young |Carl June

HighlightsThe efficacy of chimeric antigen receptor (CAR) T cells targeting solid tumors is constrained by target heterogeneity, treatment-associated toxicities, and immunosuppressive factors in the tumor microenvironment, such as poor T cell infiltration, metabolic stress, and T cell exhaustion. Toxicities associated with CAR T cell therapies can limit administration of therapeutic doses of CAR T cells.